EMERGENT BIOSOLUTIONS INC. Current Liabilities
EMERGENT BIOSOLUTIONS INC. (EBS) had Current Liabilities of $122.80 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Liabilities, Current $122.80M.
- 2026-03-31: Liabilities, Current $148.70M.
- 2025-12-31: Liabilities, Current $132.20M.
- 2025-09-30: Liabilities, Current $136.50M.
| Period end | Liabilities, Current | Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $122.80M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $148.70M 10-Q · filed 2026-05-01 | |
| 2025-12-31 | $132.20M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $136.50M 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $127.10M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $111.90M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $162.40M 10-K · filed 2026-02-27 | |
| 2024-09-30 | $229.90M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $619.70M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $630.20M 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $651.30M 10-K · filed 2025-03-04 | |
| 2023-09-30 | $664.00M 10-Q · filed 2023-12-11 | |
| 2023-06-30 | $693.20M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $1.22B 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $1.23B 10-K · filed 2024-03-08 | $1.23B 10-K · filed 2023-03-01 |
| 2022-09-30 | $264.40M 10-Q · filed 2023-12-11 | $268.40M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $276.70M 10-Q · filed 2022-08-02 | |
| 2022-03-31 | $249.20M 10-Q · filed 2022-04-29 | |
| 2021-12-31 | $374.00M 10-K/A · filed 2023-12-11 | $373.80M 10-K · filed 2022-02-25 |
| 2021-09-30 | $365.40M 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $377.80M 10-Q · filed 2021-07-30 | |
| 2021-03-31 | $370.20M 10-Q · filed 2021-04-30 | |
| 2020-12-31 | $384.50M 10-K · filed 2022-02-25 | |
| 2020-09-30 | $299.30M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $293.70M 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $207.10M 10-Q · filed 2020-05-01 | |
| 2019-12-31 | $216.30M 10-K · filed 2021-02-19 | |
| 2019-09-30 | $275.30M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $301.20M 10-Q · filed 2019-08-02 | |
| 2019-03-31 | $248.40M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $200.40M 10-K · filed 2020-02-25 | |
| 2018-09-30 | $102.01M 10-Q · filed 2018-11-02 | |
| 2018-06-30 | $96.81M 10-Q · filed 2018-08-03 | |
| 2018-03-31 | $86.87M 10-Q · filed 2018-05-04 | |
| 2017-12-31 | $100.10M 10-K · filed 2019-02-22 | $100.07M 10-K · filed 2018-02-23 |
| 2017-09-30 | $75.43M 10-Q · filed 2017-11-03 | |
| 2017-06-30 | $72.93M 10-Q · filed 2017-08-04 | |
| 2017-03-31 | $67.71M 10-Q · filed 2017-05-05 | |
| 2016-12-31 | $105.86M 10-K · filed 2018-02-23 | |
| 2016-09-30 | $110.31M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $103.86M 10-Q · filed 2016-08-05 | |
| 2016-03-31 | $90.45M 10-Q · filed 2016-05-06 | |
| 2015-12-31 | $99.61M 10-K · filed 2017-02-28 | |
| 2015-09-30 | $88.72M 10-Q · filed 2015-11-06 | |
| 2015-06-30 | $86.96M 10-Q · filed 2015-08-06 | |
| 2015-03-31 | $80.30M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $92.94M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $81.42M 10-Q · filed 2014-11-10 | |
| 2014-06-30 | $76.43M 10-Q · filed 2014-08-08 | |
| 2014-03-31 | $72.32M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $56.65M 10-K · filed 2015-03-09 | |
| 2013-09-30 | $56.63M 10-Q · filed 2013-11-08 | |
| 2013-06-30 | $48.78M 10-Q · filed 2013-08-06 | |
| 2013-03-31 | $43.54M 10-Q · filed 2013-05-03 | |
| 2012-12-31 | $61.91M 10-K · filed 2014-03-10 | |
| 2012-09-30 | $50.57M 10-Q · filed 2012-11-01 | |
| 2012-06-30 | $44.47M 10-Q · filed 2012-08-03 | |
| 2012-03-31 | $42.99M 10-Q · filed 2012-05-04 | |
| 2011-12-31 | $71.05M 10-K · filed 2013-03-08 | |
| 2011-09-30 | $68.93M 10-Q · filed 2011-11-04 | |
| 2011-06-30 | $72.50M 10-Q · filed 2011-08-05 | |
| 2010-12-31 | $75.72M 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |